Empagliflozin clinical trials
Pro Research Analysisby 
Searched over 200M research papers
Empagliflozin Clinical Trials: Efficacy, Safety, and Expanded Indications
Empagliflozin in Type 2 Diabetes: Safety and Cardiovascular Outcomes
Large-scale clinical trials have shown that empagliflozin is safe and well-tolerated in patients with type 2 diabetes (T2DM). Across pooled analyses of over 15,000 patient-years, the rates of adverse events, including severe and serious events, were similar between empagliflozin and placebo groups. The risk of hypoglycemia was not increased except in those also taking sulfonylureas. Genital infections were more common with empagliflozin, but urinary tract infections, volume depletion, bone fractures, cancer, renal events, and other serious complications were similar to placebo. These findings support a favorable benefit–risk profile for empagliflozin in T2DM management .
The EMPA-REG OUTCOME trial further demonstrated that empagliflozin significantly reduced the risk of major adverse cardiovascular events, heart failure hospitalizations, and all-cause hospital admissions in patients with T2DM and atherosclerotic cardiovascular disease. The reduction in cardiovascular events was greater when considering both first and recurrent events, highlighting the drug’s impact on overall cardiovascular risk .
Empagliflozin in Chronic Kidney Disease
In patients with T2DM and moderate to severe chronic kidney disease (CKD), empagliflozin did not raise new safety concerns. The rates of serious adverse events, discontinuations, and specific concerns such as lower limb amputations and acute renal failure were similar to placebo. Notably, empagliflozin was associated with lower risks of hyperkalemia and edema, suggesting additional renal and metabolic benefits in this population .
Empagliflozin in Heart Failure: Acute and Chronic Settings
Empagliflozin has shown significant benefits in heart failure, regardless of diabetes status. In patients hospitalized for acute heart failure, empagliflozin led to greater clinical benefit compared to placebo, including reduced death, fewer heart failure events, and improved symptoms and quality of life over 90 days. These benefits were consistent across patients with different ejection fractions and whether or not they had diabetes, and the drug was well tolerated .
In non-diabetic patients with heart failure and reduced ejection fraction (HFrEF), empagliflozin improved left ventricular function, reduced heart size, and enhanced exercise capacity and quality of life compared to placebo, supporting its use beyond glycemic control . However, in a separate trial of low-risk HFrEF patients with mild symptoms, empagliflozin did not significantly change NT-proBNP levels, daily activity, or health status over 12 weeks, suggesting that benefits may be more pronounced in higher-risk or more symptomatic patients .
Empagliflozin in Type 1 Diabetes
The EASE trials evaluated empagliflozin as an add-on to insulin in type 1 diabetes (T1D). Empagliflozin improved glycemic control, reduced weight, increased time-in-range for glucose, lowered insulin requirements, and reduced blood pressure without increasing hypoglycemia risk. However, higher doses (10 mg and 25 mg) were associated with increased diabetic ketoacidosis, while the 2.5 mg dose had a ketoacidosis rate similar to placebo, suggesting that lower doses may be safer in T1D .
Novel Indications: Depression and Brain Insulin Sensitivity
A recent clinical trial found that empagliflozin, when added to citalopram, led to greater improvement in depression symptoms compared to citalopram alone in patients with major depressive disorder, indicating potential neuromodulatory and anti-inflammatory benefits that warrant further study .
Additionally, in patients with prediabetes, empagliflozin restored hypothalamic insulin sensitivity, which was linked to reductions in fasting glucose and liver fat. This suggests that empagliflozin may help reverse brain insulin resistance, potentially benefiting metabolic health and body fat distribution .
Ongoing Research: Post-Myocardial Infarction
The EMPACT-MI trial is currently evaluating empagliflozin’s safety and efficacy in patients hospitalized for myocardial infarction who are at high risk for developing heart failure. This large, multinational study aims to determine whether empagliflozin can reduce heart failure hospitalizations and mortality in this high-risk group .
Conclusion
Empagliflozin has demonstrated robust safety and efficacy in a range of clinical trials, showing benefits in glycemic control, cardiovascular and renal outcomes, heart failure management, and even potential effects on depression and brain insulin sensitivity. Its expanding indications and favorable safety profile make it a valuable therapeutic option for diverse patient populations, with ongoing research likely to further define its role in clinical practice.
Sources and full results
Most relevant research papers on this topic